Compare Recursion Pharmaceuticals Inc (RXRX) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Wells Fargo & Co — how do they compare? Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.81B), while Wells Fargo & Co trades at $87.35 (market cap $264.66B). The key difference: Wells Fargo & Co is far larger — about 146.2× Recursion Pharmaceuticals Inc's market cap, and Wells Fargo & Co pays a 2.29% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | WFC | |
|---|---|---|
Market Cap | $1.81B | $264.66B |
Sector | Health | Financials |
52-Week High | $6.79 | $96.40 |
52-Week Low | $2.84 | $73.42 |
Enterprise Value | $1.33B | — |
Dividend Yield | — | 2.29% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
